Aclaris Therapeutics Q4 Earnings Summary & Key Takeaways
Benzinga Insights 8 months ago
Earnings
Aclaris Therapeutics (NASDAQ:ACRS) reported its Q4 earnings results on Thursday, February 26, 2026 at 06:58 AM.
Here's what investors need to know about the announcement.
Earnings
Aclaris Therapeutics missed estimated earnings by -14.29%, reporting an EPS of $-0.16 versus an estimate of $-0.14.
Revenue was down $7.92 million from the same period last year.
Analysis of Past Earnings
During the previous quarter, the company beat on EPS by $0.02, leading to a 2.2% increase share price change the next day.
Here's a look at Aclaris Therapeutics's past performance:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.14 | -0.13 | -0.12 | -0.27 |
| EPS Actual | -0.12 | -0.13 | -0.12 | -0.10 |
| Revenue Estimate | 1.48M | 1.39M | 4.78M | 5.85M |
| Revenue Actual | 3.30M | 1.78M | 1.46M | 9.21M |
To track all earnings releases for Aclaris Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.